The drug screening identified several drugs, including Tazemetostat for EZH2 and Lithium compounds for GSK3β, which could offer promising therapeutic strategies; however, further studies are required to validate their efficacy and safety in HCC treatment. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.